RB1 and neoplasm: For example, although 72 (61.5%) mutations, including an oncogenic RB1 S249* mutation, were shared between the SMBO-109 PDO and the tumor from which it was derived, ERBB2 amplification was present only in the organoid line but not in the tumor (Fig. 2A, B).